Chronic Conditions Dominate Global Health Burden, GBD 2019 Study Reports Meghna A Singhania23 May 2025 5:10 PM ISTChronic care needs account for the majority of global disease burden-comprising 68% of all disability-adjusted life years (DALYs) and over 86% of...
Meril presents successful LANDMARK RCT one-year results at prestigious EuroPCR 2025 Deeksha Bhandari23 May 2025 4:58 PM ISTFirst-of-its-kind head-to-head TAVI trial reinforces the performance and safety of the Next Gen Myval THV series
Age and Blood Pressure Drive Arterial Stiffness Progression in Japanese Adults: New Risk Score Developed Meghna A Singhania23 May 2025 4:26 PM ISTAge, blood pressure, and metabolic risk factors can predict arterial stiffness progression over five years, a recent study has reported.Published in...
Alembic Pharma bags USFDA nod for high BP traetment drug Ruchika Sharma23 May 2025 3:29 PM ISTVadodara: Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for Amlodipine...
Senores Pharma boosts heart health portfolio with acquisition of USFDA approved Enalapril Tablets ANDA from Wockhardt Ruchika Sharma23 May 2025 11:00 AM ISTAhmedabad: Senores Pharmaceuticals Limited (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed ...
Complete Revascularization Offers Long-Term Advantage in STEMI With Multivessel Disease, Study Finds Medha Baranwal23 May 2025 8:30 AM ISTDenmark: A decade after undergoing primary treatment, patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery...
Ajanta Pharma Launches Met-XL D to Improve Outcomes for Heart Failure and Post-Myocardial Infarction Patients Deeksha Bhandari22 May 2025 12:30 PM ISTAjanta Pharma, one of the leaders in the cardiology segment has launched the fixed dose combination of Metoprolol and Dapagliflozin under the brand...
Meta-analysis finds no Benefit in Routine Use of cerebral embolic protection During TAVI- EuroPCR 2025 Dr. Kamal Kant Kohli22 May 2025 12:00 PM ISTThe EuroPCR Course Directors have chosen three major late-breaking trials to be unveiled at EuroPCR 2025. These were selected for their strong design,...
Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study Dr. Garima Soni22 May 2025 11:30 AM ISTAhmedabad: Azmarda, an innovator brand of Sacubitril/Valsartan, demonstrated superior efficacy compared to generic Sacubitril/Valsartan in patients...
FFR-Guided PCI Shows Benefit in TAVI Patients with Intermediate CAD: The FAITAVI trial(EuroPCR 2025) Dr. Kamal Kant Kohli22 May 2025 8:45 AM ISTEuroPCR Course Directors have selected three significant late-breaking trials for first-time presentation at EuroPCR 2025, chosen for their robust...
Sacubitril/Valsartan may Improve Diabetic Cardiomyopathy via Immunomodulation of Inflammation: Study Dr. Shravani Dali22 May 2025 8:45 AM ISTA recent study published in Cardiovascular Diabetology reveals that Sacubitril/Valsartan, a combination of a neprilysin inhibitor and an angiotensin...
4C-ACS Trial Supports 1-Month DAPT De-Escalation in East Asian ACS Patients: EuroPCR 2025 Dr. Kamal Kant Kohli22 May 2025 7:30 AM ISTWhile dual antiplatelet therapy (DAPT) has been the standard for managing acute coronary syndrome (ACS) patients undergoing PCI, there is growing...
